comparemela.com

Morgan Kervitsky News Today : Breaking News, Live Updates & Top Stories | Vimarsana

U S FDA Clears MYCO-001 for Multi-Site Government Funded

DENVER, June 17, 2022 (GLOBE NEWSWIRE) Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology.

United statesMorgan kervitskyJessica rigglemanJosh bartchMichaelp bogenschutzPeter hendricksJoshua bartchMatthew johnsonMydecine innovations group incRegulatory affairsNational institutes of healthDrug administrationDepartment of psychiatryDepartment of health behaviorBehavioral sciences at johns hopkins universityMydecine innovations group

Mydecine Announces First Quarter 2022 Financial Results and

DENVER, May 16, 2022 (GLOBE NEWSWIRE) Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a.

United statesMorgan kervitskyJosh bartchJoshua bartchMydecine innovations group incHealth canada special access programDrug developmentMydecine innovations groupClinical researchInnovations groupInvestigational new drug applicationInstitutional review boardCessation studyNew chemical entitiesHighlights duringFirst quarter

Mydecine Reports Financial Results for the Fiscal Year 2021 and Provides a Business Update

01.04.2022 - MYCO-001 Smoking Cessation Clinical Trial Moves Forward Following Conditional IRB Approval Company Advances IP Portfolio With New Patent Applications Covering Novel Molecule Families DENVER, March 31, 2022 (GLOBE NEWSWIRE) - Mydecine Innovations .

United statesMorgan kervitskyVictoria haleSaeid babaeiGordon nealJosephine wuJosh bartchJoshua bartchMatthew johnsonJohns hopkins universityUniversity of alabamaMaster collaboration research agreementMydecine innovations groupClinical researchYork universityMydecine innovations group inc

Mydecine Partners with Combat Stress to Treat Post-Traumatic Stress Disorder in Veterans

Study further supports the expansion of clinical trials of MYCO-001 for the treatment of PTSD among the Veteran populationDENVER, Jan. 24, 2022 Mydecine Innovations Group , a biotechnology.

United statesUnited kingdomCity ofMorgan kervitskyJosh bartchRakesh jetlyJoshua bartchDominic murphyKing college londonCanadian armedUnited kingdom psychological trauma societyMydecine innovations group incHead of research at combatMydecine innovations groupInnovations groupCombat stress

Mydecine Signs LOI with Maya to Co-Develop a Novel

DENVER, Dec. 22, 2021 (GLOBE NEWSWIRE) Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NF.F) (“Mydecine” or the “Company”), a biotechnology.

United statesMorgan kervitskyDamon michaelsJoshua bartchMindleap healthJohns hopkins universityMydecine innovations group incMindleap health incMydecine innovations groupMydecine coColorado public benefit corporationInnovations groupDigital therapeuticsMydecine co founderChief executiveAequitas neo exchange myco ne

vimarsana © 2020. All Rights Reserved.